Goal: The primary
goal of my blog series is to contribute to SITC’s mission in educating
patients, clinicians, and researchers about the recent advancements in
immunotherapy. I am particularly interested in the use of genetically modified
(non-pathogenic) viruses as immune modulators for cancer treatment.
In this
introductory edition of my blog series, I would like to provide an overview of
cancer immunotherapy and a brief description on why immunotherapies may not
always work well due to heterogeneity in tumor phenotypes and various
mechanisms that suppress immune response against cancers.
Target audience: Patients and their families, clinicians,
and researchers.
